These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 3311840)

  • 1. [Characterization of antigens reacting with vitiligo and cytoplasmic melanoma antibodies].
    Presser HJ; Morenz J; Höfs T; Zugehör M; Kühne KH; Brödemann M
    Dermatol Monatsschr; 1987; 173(8):441-5. PubMed ID: 3311840
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
    Hertz KC; Gazze LA; Kirkpatrick CH; Katz SI
    N Engl J Med; 1977 Sep; 297(12):634-7. PubMed ID: 331108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology and immunotherapy of human malignant melanoma.
    Bystryn JC
    Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of antibodies to melanoma cells in vitiligo by 125I-labeled SpA antibody binding assay].
    Mori N; Shimada K; Satoh N; Nagao S; Iijima S; Kanzaki T
    Nihon Hifuka Gakkai Zasshi; 1986 Jul; 96(8):835-8. PubMed ID: 3784053
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
    Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
    Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of autoantigens by patients with melanoma.
    Houghton AN; Vijayasaradhi S; Bouchard B; Naftzger C; Hara I; Chapman PB
    Ann N Y Acad Sci; 1993 Aug; 690():59-68. PubMed ID: 8368771
    [No Abstract]   [Full Text] [Related]  

  • 7. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
    Höfs T
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis of melanocytes in vitiligo results from antibody penetration.
    Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
    J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
    Cui J; Bystryn JC
    Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitiligo and malignant melanoma.
    Fodor J; Bodrogi I
    Neoplasma; 1975; 22(4):445-8. PubMed ID: 1196428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
    Fishman P; Merimski O; Baharav E; Shoenfeld Y
    Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune mechanisms in vitiligo.
    Bystryn JC
    Immunol Ser; 1989; 46():447-73. PubMed ID: 2488866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes.
    Houghton AN
    Prog Clin Biol Res; 1983; 119():199-205. PubMed ID: 6867027
    [No Abstract]   [Full Text] [Related]  

  • 15. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
    Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
    J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
    Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current remedies for vitiligo.
    Abu Tahir M; Pramod K; Ansari SH; Ali J
    Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why tyrosinase for treatment of melanoma.
    Song YH
    Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.
    Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP
    Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.